432 related articles for article (PubMed ID: 29327219)
1. Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.
Auffret M; Drapier S; Vérin M
Clin Drug Investig; 2018 Apr; 38(4):287-312. PubMed ID: 29327219
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine in the treatment of Parkinson's disease.
Menon R; Stacy M
Expert Opin Pharmacother; 2007 Aug; 8(12):1941-50. PubMed ID: 17696795
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
Neef C; van Laar T
Clin Pharmacokinet; 1999 Sep; 37(3):257-71. PubMed ID: 10511920
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
7. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
8. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Carbone F; Djamshidian A; Seppi K; Poewe W
CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
11. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.
Junginger HE
Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S57-75. PubMed ID: 12460716
[TBL] [Abstract][Full Text] [Related]
12. Sublingual apomorphine therapy as an alternative to complex continuous infusion pumps in advanced Parkinson's disease treatment: a district nurse-led intervention.
Macaulay K
Br J Community Nurs; 2022 Jul; 27(7):328-335. PubMed ID: 35776556
[TBL] [Abstract][Full Text] [Related]
13. Role of apomorphine in the treatment of Parkinson's disease.
Boyle A; Ondo W
CNS Drugs; 2015 Feb; 29(2):83-9. PubMed ID: 25676564
[TBL] [Abstract][Full Text] [Related]
14. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
Jenner P; Katzenschlager R
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
[TBL] [Abstract][Full Text] [Related]
15. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
16. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
17. Future delivery systems for apomorphine in patients with Parkinson's disease.
van Laar T; Van der Geest R; Danhof M
Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
[No Abstract] [Full Text] [Related]
18. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
LeWitt PA
Neurology; 2004 Mar; 62(6 Suppl 4):S8-11. PubMed ID: 15037665
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
[TBL] [Abstract][Full Text] [Related]
20. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
Henriksen T
Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
